Individual case reports
Patient S1 is a 53-year-old female (Pucallpa, Peru), 67 kg weight, 163 cm height, and blood pressure of 100/70 mmHg. She was diagnosed with diabetes mellitus 12 years previously, and current diagnoses include diabetes and obesity. S1 was treated with Glibenclamide 5 mg every 12 h for 3 months, then 5 mg every 24 h for five years. Because her blood sugar levels remained high, treatment was modified to add a Metformin 850 mg tablet during breakfast and dinner, in addition to Glibenclamide 5 mg in the afternoon for four years. Despite the modifications of the pharmaceutical treatments, S1 maintained high blood sugar levels (175–200 mg/dl).
GlucoMedix® 2 ml (40 drops) was added to the dual pharmacological treatment, 30 min before breakfast and dinner, in addition to 2 ml (40 drops) before sleep, for a daily total dose of 6 ml. A decrease in blood sugar levels to 62 mg/dl was recorded 7 days after the start of the use of GlucoMedix®, so Glibenclamide was withdrawn from the pharmacological treatment.
After the second week of starting the GlucoMedix® blood sugar levels were maintained between 62 and 65 mg/dl. This change prompted a reduction in the dose of Metformin to ½ tablet (425 mg) during breakfast and dinner, which resulted in regularized blood sugar levels between 80 and 110 mg/dl.
During the third week of GlucoMedix® treatment, it was possible to completely withdraw the pharmacological portion of the treatment, leaving only the use of GlucoMedix® and a low carb diet, which resulted in the maintained blood sugar levels of < 130 mg/dl. With the use of GlucoMedix® and the removal of the low carb diet, blood sugar levels remained between 130 and 145 mg/dl.
Patient S2 is a 50-year-old female (Pucallpa, Peru), 59 kg weight, 153 cm height, and blood pressure of 110/70 mmHg. She was diagnosed with diabetes mellitus 3 years ago, and current diagnoses include diabetes and obesity. S2 was on a Vildagliptin treatment (Galvus®) 50 mg daily for 6 months and maintained high blood sugar levels of 180–200 mg/dl.
The high blood sugar levels prompted the removal of the pharmacological treatment and start of treatment with GlucoMedix® 2 ml (40 drops) 30 min before breakfast and dinner, in addition to 2 ml (40 drops) before sleeping, for a total daily dose of 6 ml, alongside a low carb diet. Blood sugar levels were recorded being between 110 and 130 mg/dl, 7 days after the start of the use of GlucoMedix®.
Patient R1 is a 53-year-old male (Pucallpa, Peru), 112 kg weight, 180 cm height, and blood pressure of 110/80 mmHg. His current diagnosis is type 1 obesity and diabetes. He reported blood sugar levels of 127 mg/dl in monthly control examinations 2 years ago, as well as being overweight.
To improve blood sugar levels, R1 began treatment with GlucoMedix® 2 ml (40 drops) 30 min before breakfast and dinner, plus 2 ml (40 drops) before sleeping, for a total daily dose of 6 ml, together with a low carb diet, which resulted in a decrease in blood sugar levels between 85 and 105 mg/dl 8 days after starting the use of GlucoMedix®. Furthermore, the patient continued to maintain blood sugar values between 100 and 120 mg/dl with the use of GlucoMedix® and without incorporating a low carb diet.
Patient O1 is a 59-year-old male (Pucallpa, Peru), 84 kg weight, 170 cm height, and blood pressure of 130/82 mmHg. He was diagnosed with type 2 diabetes 24 years ago, and current diagnoses include diabetes and obesity. He was treated with Glibenclamide 5 mg every twelve hours and Metformin 850 mg during breakfast and dinner. During the prior 15 years, despite the treatment, O4 had maintained high blood sugar levels (200–270 mg/dl).
The patient added GlucoMedix® 2 ml (40 drops) 30 min before breakfast and dinner, also 2 ml (40 drops) before sleeping, for a total daily dose of 6 ml. Together with the dual drug treatments and a low carb diet, after 4 weeks the blood sugar levels were reduced to 121 mg/dl. Treatment continued thereafter, with the patient expressing satisfaction with the addition of the phytotherapy.
Patient R2 is a 54-year-old male (Pucallpa, Peru), 72 kg weight, 171 cm height, and blood pressure of 100/70 mmHg. He was diagnosed with diabetes mellitus 17 years ago, and current diagnoses include diabetes and chronic kidney disease, as evidenced by clinical chemistry (i.e., urea 40 and creatinine 2.1). From 2004 until 2010 he was treated with Metformin 850 mg at breakfast and dinner, in addition to Glibenclamide 5 mg during breakfast and dinner. This medical approach resulted in blood sugar levels of 145–205 mg/dl.
The patient was diagnosed with chronic kidney disease in 2010, for which he was treated by a nephrologist, plus an endocrinologist exchanged the Metformin and Glibenclamide for Insulin 15 IU at breakfast and dinner. However, the patient rejected Insulin therapy in 2011, and proceeded to change his lifestyle (i.e., no alcohol, no tobacco, low carbohydrate diet, and no sugar). With these medical and lifestyle changes he managed to reduce blood sugar levels to 130 - 165 mg/dl.
The patient administered GlucoMedix® 2 ml (40 drops) 30 minutes before breakfast and dinner, plus 2 ml (40 drops) before sleeping, for a total daily dose of 6 ml. This treatment decreased glucose to 110 - 120 mg/dl at 12 days after the start of the use of GlucoMedix®. At 20 days the glucose level reached 78 - 116 mg/dl, and he continued to maintain those values thereafter for more than one year.
Patient R3 is a 65-year-old female (Tarapoto, Dept. San Martin, Peru), 64 kg weight, 154 cm height, and medicated blood pressure of 135/75 mmHg. She has had a diagnosis of type 2 diabetes for 20 years and a history of mismanagement of her disease, as evidenced by Hb A1C greater than 10%. Before the start of the use of GlucoMedix®, the patient was managed with combined therapy of Metformin 850 mg in conjunction with Insulin six years earlier. As an Insulin-dependent diabetic she has been maintained on Glargine Insulin (Lantus) 28 IU/day. She exhibited other comorbidities consistent with Metabolic Syndrome, such as hypertension grade I (Irbesartan 150 mg once daily), mixed dyslipidemia, and obesity grade I, and chronic collateral damage as a poorly controlled diabetic patient, such as stage 2 to 3 kidney failure (mild to medium kidney damage) and mild to moderate proliferative diabetic retinopathy.
Between December 2019 and July 2021, the patient replaced Metformin 850 mg with oral GlucoMedix®. At the time of the start of the all-natural treatment, the patient was poorly managed, having high glycosylated hemoglobin values (A1C > 10%) and fluctuating glycemic levels (> 150 mg/dL). The last baseline control of Hb A1C was 11.2%, and the lipid profile showed mild mixed dyslipidemia. The initial dose of GlucoMedix® was 2 ml (40 drops) twice daily, 20 to 30 min before meals, diluted in water, for a total daily dose of 4 ml. At the same time, the patient was instructed to change her style of eating, gradually decreasing the intake of complex carbohydrates and saturated fats, and ceasing sugar from the diet. Frequently used medicines were not initially modified with the exception of discontinuing Metformin.
The first month the patient reported daily glycemic controls with a tendency to decrease, which prompted a decrease in the daily insulin dose, at a rate of 2 IU, each time the patient achieved glycemia less than 100 mg/dL. Within approximately 1 month the level managed to drop from 28 to 18 IU/day, a decrease that continued until January 2020, stabilizing at 14 IU - Insulin doses that maintained a daily glycemic level below 140 mg/dL, and remaining at this level for more than a year. The A1C levels reduced to values between 5.7% to 6.5% to the present.
A decrease in the level of glycemia was found, the effect was greater if it was accompanied by a change in the eating style in a sustained manner. In the initial adaptation phase, the patient reported symptoms similar to that of hypoglycemia (feeling of weakness, early fatigue, and nausea), so the dose of 2 ml (40 drops) twice daily was temporarily decreased to 2 ml (40 drops) once daily before breakfast, resuming it after 5 days. Improvements were observed in the results of quarterly control laboratory examinations.
During 2020, auxiliary glycemic control tests were performed on a daily and quarterly basis, as well as other complementary tests (A1C and lipid profile). It was observed that the main beneficial effect of the GlucoMedix® extract was that of being anti-hyperglycemic, and as an adjunct to her main treatment (insulin). A lipid-lowering effect was observed. However, more controls are required to determine if it was the result of the consumption of the phytotherapy, or due to other factors. The anti-hyperglycemic effect of the product substantially improves Hb A1C levels, making them acceptable compared to previously recorded baseline level of 11.2%.
Furthermore, the levels of total cholesterol, triglycerides, and LDL were regularized, achieving normal or low-risk levels (assessments in March 2020, September 2020, and January 2021). But more controls are needed to determine whether the beneficial effects are due to the Stevia - Uncaria extract and/or to any substantial change in nutrition.
The patient’s compliance/adherence on GlucoMedix® was better than when using pharmaceutical medications (e.g., Glibenclamide, Metformin), thus favoring better long-term results and non-abandonment of adjuvant treatment(s). The gradual decrease in the dose of insulin helped to avoid greater long-term weight gain in the patient, which would have been more detrimental to her Metabolic Syndrome. Furthermore, the patient noted another benefit - the loss of the sensation of bitterness in the mouth that she had reported when using oral Metformin or Glibenclamide.